Company Overview
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.06.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -90.0%.
- 5-Year Trend Long-term compounding — profit CAGR -39.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -90.00% |
Compounded Profit Growth
| 5 Years: | -39.13% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +657.78% |
| 6 Months: | +39.47% |
| 3 Months: | +21.14% |
| 1 Month: | +30.53% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)56.45 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -39.1% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ALMS Alumis Inc. R2K | 27.28 | -15.33 | $3.37B | 0.00% | -134.01% | -64.57% | - | -39.13% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 17.39M | 2.67M | 2.07M | 1.93M | 1.74M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | 118.92M | 143.21M | 117.36M | 98.37M | 100.15M |
| Operating Income | - | -37.62M | -43.76M | -47.59M | -56.14M | - | - | -101.53M | -140.54M | -115.29M | -96.44M | -98.41M |
| EBITDA | - | - | - | - | - | - | - | -100.69M | -139.67M | -114.38M | -95.58M | -97.54M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | -98.96M | 50.76M | -110.75M | -92.93M | -93.05M |
| Tax Provision | - | - | - | - | - | 0 | - | - | -8.56M | 0 | 0 | - |
| Net Income | -36.03M | -36.29M | -43.38M | -49.85M | -56.51M | - | - | -98.96M | 59.32M | -110.75M | -92.93M | -93.05M |
| Diluted EPS | - | -17.13 | -19.76 | -21.03 | -23.10 | -1.73 | - | -1.82 | 0.57 | -1.06 | - | -0.74 |
| R&D Expense | - | 32.85M | 37.79M | 41.96M | 48.56M | 87.82M | - | 96.62M | 108.75M | 97.84M | - | 81.54M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 24.05M |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 113.85M | 158.17M | 300.75M | 477.85M |
| Operating Income | -113.85M | -158.17M | -300.75M | -453.80M |
| EBITDA | -113.60M | -156.89M | -297.60M | -450.31M |
| Interest Expense | - | - | - | - |
| Pretax Income | -111.93M | -154.99M | -294.23M | -251.89M |
| Tax Provision | - | - | 0 | -8.56M |
| Net Income | -111.93M | -154.99M | -294.23M | -243.32M |
| Diluted EPS | -2.91 | -2.99 | -10.38 | -2.32 |
| R&D Expense | - | 137.68M | 265.55M | 386.00M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | 108.17M | 89.61M | 340.99M | 411.94M |
| Current Assets | 102.56M | 53.36M | 306.19M | 318.23M |
| Cash & Equivalents | 25.61M | 46.00M | 169.53M | 89.67M |
| Inventory | - | - | - | - |
| Receivables | 500.00K | 722.00K | 1.81M | 2.08M |
| Total Liabilities | 303.41M | 428.87M | 80.89M | 110.64M |
| Current Liabilities | 13.35M | 20.87M | 50.91M | 73.32M |
| Long Term Debt | - | - | - | - |
| Total Debt | 1.78M | 32.58M | 30.72M | 36.91M |
| Total Equity | -195.24M | -339.26M | 260.10M | 301.30M |
| Shares Outstanding | 51.84M | 51.84M | 54.41M | 104.71M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -107.72M | -129.97M | -255.08M | -369.52M |
| Investing Cash Flow | -68.75M | 60.47M | -113.79M | 287.88M |
| Financing Cash Flow | 101.63M | 89.68M | 492.37M | 2.07M |
| Capital Expenditure | -2.41M | -4.50M | -1.73M | -653.00K |
| Free Cash Flow | -110.13M | -134.47M | -256.81M | -370.18M |
| Net Change in Cash | -74.85M | 20.18M | 123.50M | -79.58M |
| Share Buybacks | - | 64.00K | 6.00K | 17.00K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | -1,886.9% |
| Net Margin % | - | - | - | -1,011.7% |
| ROE % | 57.3% | 45.7% | -113.1% | -80.8% |
| ROCE % | -120.1% | -230.1% | -103.7% | -134.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 5.81% | 7.17M | $195.84M |
| 2 | Deep Track Capital, Lp | 5.49% | 6.77M | $184.96M |
| 3 | Samsara BioCapital, LLC | 5.14% | 6.35M | $173.29M |
| 4 | Foresite Capital Management V, LLC | 4.78% | 5.90M | $161.05M |
| 5 | venBio Partners LLC | 3.67% | 4.53M | $123.67M |
| 6 | Foresite Capital Management VI LLC | 3.44% | 4.25M | $116.00M |
| 7 | Vanguard Capital Management LLC | 3.27% | 4.03M | $110.12M |
| 8 | Cormorant Asset Management, LP | 3.20% | 3.95M | $107.85M |
| 9 | Nextech Invest, Ltd. | 2.87% | 3.54M | $96.70M |
| 10 | Price (T.Rowe) Associates Inc | 2.66% | 3.29M | $89.76M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ALMS
Stifel and Guggenheim Stay Bullish on Alumis (ALMS)
Alumis Inc. (NASDAQ:ALMS) is one of the Top 10 Hot Stocks with the Highest Upside Potential. As of June 29, analysts are bullish on Alumis Inc. (NASDAQ:ALMS), giving the stock a consensus Buy rating. The 12-month median price target of $39.…
Analyst Sentiment On Alumis (ALMS) Remains Strong Following Q1 Results And Envudeucitinib Pipeline Advancements
With an analyst consensus upside of 79.4%, Alumis Inc. (NASDAQ:ALMS) ranks among the under-the-radar stocks with massive upside for 2026. Alumis Inc. (NASDAQ:ALMS) drew three analyst price target raises after reporting Q1 results and advanc…
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter
This biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory diseases using proprietary TYK2 inhibitors.
Is Alumis (ALMS) Trading Short-Term Revenue for a Leaner, More Focused Business Model?
Alumis Inc. recently reported first-quarter 2026 results, with revenue of US$1.74 million versus US$17.39 million a year earlier and a net loss of US$93.05 million compared with US$98.96 million previously. Despite sharply lower revenue, th…
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares
This clinical-stage biotech develops therapies for rare muscle diseases, leveraging its FORCE platform to target significant unmet needs.
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors
Ocular Therapeutix delivers ophthalmic therapies with hydrogel technology and a pipeline targeting retinal and glaucoma conditions.
ALMS — Frequently Asked Questions
What is the current share price of Alumis Inc. (ALMS)?
As of 2026-07-14 21:23 PDT, Alumis Inc. (ALMS) trades at $27.28 on NasdaqGS. Its 52-week range is $3.31 to $30.30.
What is the market capitalisation of ALMS?
Alumis Inc. (ALMS) has a market capitalisation of $3.37B on NasdaqGS.
What is the P/E ratio of ALMS?
ALMS trades at a trailing price-to-earnings (P/E) ratio of -15.33. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 5.42.
What is the return on equity (ROE) of ALMS?
ALMS has a return on equity (ROE) of -64.57%. Its return on capital employed (ROCE) is -134.01%.
Is ALMS a good stock to buy?
This page provides a data-driven analysis of Alumis Inc. (ALMS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.